Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy

Epilepsia

Volumn 38, Issue 3, 1997, Pages 324-333

  Rosenfeld, W E ^a,d   Liao, S ^b   Kramer, L D ^b   Anderson, G ^c   Palmer, M ^b   Levy, René H ^c   Nayak, R K ^b  

^a St Luke's Hospital   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d St Luke's North Medical Building ^*  (United States)

Author keywords

Anticonvulsants; Epilepsy; Pharmacokinetics Drug interactions; Topiramate; Valproic acid

Indexed keywords

TOPIRAMATE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VALPROIC ACID;

EID: 0030956491     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01124.x     Document Type: Article

References (34)

1. Shank RP, Gardocki JF, Vaught JL, el al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
2. Ramsay RE, Slater JD. Antiepileptic drugs in clinical development. Epilepsy Res 1993;10(suppl):45-67.
3. Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans without intravenous data [Abstract]. J Clin Pharmacol 1994;34:1029.
4. Kramer LD. The pre-clinical profile of topiramate: a structurally novel anticonvulsant drug [Abstract]. The 20th International Epilepsy Congress, Oslo, Norway, July 1993.
5. Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant, topiramate in healthy men [Abstract]. Pharm Res 1994;11(suppl):S-336.
6. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans [Abstract]. Epilepsia 1988;29:662.
7. Gisclon LG, Curtin CR, Krarner LD, Sachdeo RC, Levy RH. The steady-state (SS) pharmacokinetics of phenytoin (Dilantin) and of topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy [Abstract]. Epilepsia 1994;35(suppl 8):54.
8. Sachdeo RC, Sachdeo SK. Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepinc in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
9. Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interactions with topiramate using CYP450 inhibition spectrum [Abstract]. Epilepsia 1995;36(suppl 4):47.
10. Doose DR. Rosenfeld WE, Schaefer P, Walker SA, Nayak RK. Evaluation of the potential pharmacokinetic interaction between topiramate and the oral contraceptive combination, norethindrone/ ethinyl estradiol [Abstract]. J Clin Pharmacol 1994;34;1031.
11. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacokinetic properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
12. Dreifuss FE, Saniilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-85.
13. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopalhologic studies. Hepatology 1984;4:1143-52.
14. Kingsley E, Gray P, Tolman KG, Tweedale R. The toxicity of the metabolites of sodium valproate in cultured hepalocytes. J Clin Pharmacol 1983;23:178-85.
15. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991;32:716-21.
16. Cooper JM, Stubbs RJ, Palmer ME. A capillary GC assay with NPD detection for the quantification of topiramate in human plasma [Abstract]. Pharm Res 1991;10(suppl 8):19.
17. Rettenmeier AW, Howard WN, Levy RH, et al. Quantitative metabolic profiling of valproic acid in humans using automated gas Chromatographic/mass spectrometric techniques. Biomed Environ Mass Spectrom 1989;18:192-9.
18. Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225-35.
19. SAS (Statistical Analysis System). User's Guide: Statistics. Cary, NC: SAS Institute, 1982.
20. Milliken GA, Johnson DE. Analysis of messy data. New York: Van Nostrand Reinhold, 1984.
21. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: Wiley, 1980.
22. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 1982;24:543-56.
23. Bruni J, Gallo JM, Lee CS, Perchalski RJ, Wilder BJ. Interactions of valproic acid with phenytoin. Neurology 1980;30:1233-6.
24. Sansom LN, Beran RC, Schapel GJ. Interaction between phenytoin and valproate. Med J Aust 1980;2:212.
25. Ramsay RE, McManus DQ, Guterman A, et al. Carbamazepine metabolism in humans: effect of concurrent anliconvulsant therapy. Ther Drug Monit 1990;12:235-41.
26. McKee PJW, Blacklaw J, Butler E, Gillnam RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 1992;11:193-8.
27. Bruni J, Wilder BJ, Perchalski RJ, Hammond EJ, Villarreal HJ. Valproic acid and plasma levels of phenobarbital. Neurology 1980;30:94-7.
28. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DCA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
29. Jann MW, Fidone GS, Israel MK, Bonadero P. Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 1988;29:578-81.
30. Reunanen MI, Luoma P, Myllylä VV, Hokkanen E. Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res 1980;28:456-62.
31. Wagner ML, Graves NM, Leppik IE, Remmel RP, Ward DL, Shumaker RC. The effect of felbamate on valproate disposition. Clin Pharmacol Ther 1994;56:494-502.
32. Doose DR, Scott VV, Margul BL, et al. Multiple-dose pharmaco-kinetics of topiramate in healthy male subjects [Abstract]. Epilepsia 1988;29:662.
33. Levy RH. Variability in level-dose ratio of valproale: monotherapy versus polytherapy. Epilepsia 1984;25(suppl 1):S10-3.
34. Anderson GD, Acheampong AA, Wilensky AJ, Levy RH. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 1992;33:736-42.